Atea Pharmaceuticals, Inc. (AVIR)
NASDAQ: AVIR · Real-Time Price · USD
5.67
-0.17 (-2.91%)
Apr 10, 2026, 4:00 PM EDT - Market closed
Atea Pharmaceuticals Employees
Atea Pharmaceuticals had 55 employees as of December 31, 2025. The number of employees decreased by 1 or -1.79% compared to the previous year.
Employees
55
Change (1Y)
-1
Growth (1Y)
-1.79%
Revenue / Employee
n/a
Profits / Employee
-$2,879,073
Market Cap
451.74M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 55 | -1 | -1.79% |
| Dec 31, 2024 | 56 | -19 | -25.33% |
| Sep 30, 2024 | 75 | 1 | 1.35% |
| Jun 30, 2024 | 75 | 3 | 4.17% |
| Mar 31, 2024 | 74 | 1 | 1.37% |
| Dec 31, 2023 | 75 | 5 | 7.14% |
| Sep 30, 2023 | 74 | 6 | 8.82% |
| Jun 30, 2023 | 72 | 9 | 14.29% |
| Mar 31, 2023 | 73 | 9 | 14.06% |
| Dec 31, 2022 | 70 | 11 | 18.64% |
| Sep 30, 2022 | 68 | 12 | 21.43% |
| Jun 30, 2022 | 63 | 14 | 28.57% |
| Mar 31, 2022 | 64 | 22 | 52.38% |
| Dec 31, 2021 | 59 | 20 | 51.28% |
| Sep 30, 2021 | 56 | 45 | 409.09% |
| Jun 30, 2021 | 49 | 38 | 345.45% |
| Mar 31, 2021 | 42 | 31 | 281.82% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Replimune Group | 479 |
| REGENXBIO | 371 |
| ADC Therapeutics | 193 |
| Absci | 140 |
| Sutro Biopharma | 137 |
| enGene Holdings | 82 |
| Assembly Biosciences | 73 |
| Lexeo Therapeutics | 59 |
AVIR News
- 24 days ago - Top 2 Health Care Stocks That May Fall Off A Cliff This Month - Benzinga
- 5 weeks ago - Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 6 weeks ago - Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026 - GlobeNewsWire
- 6 weeks ago - Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026 - GlobeNewsWire
- 3 months ago - Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 3 months ago - Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 3 months ago - Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus - GlobeNewsWire
- 5 months ago - Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference - GlobeNewsWire